TWiV 1252: Clinical update with Dr. Daniel Griffin
This Week in Virology
Moderna's NX Spike Vaccine Insights
This chapter explores the latest developments in Moderna's NX spike vaccine, emphasizing its targeted approach and differences in reactogenicity and efficacy compared to traditional vaccines. The discussion includes listener concerns about vaccine effectiveness, personalized health advice, and the implications of waning immunity for older populations in light of increasing measles outbreaks.
In his weekly clinical update, Dr. Griffin with Vincent Racaniello discuss the continued Legionnaire’s outbreak in Harlem, invasive Asia longhorned tick and associated disease, potential Ebola outbreak in the Congo, Florida ending childhood vaccine mandates, before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, SARS-CoV-2 spillover into household/domestic dogs, real data demonstrating the benefits of COVID-19 vaccines, states that increase access to COVID-19 vaccines, effective and availability to PAXLOVID, where to find PEMGARDA, long COVID treatment center, where to go for answers to your long COVID questions, the beginning of numerous long COVID clinical studies and contacting your federal government representative to stop the assault on science and biomedical research.
Subscribe (free): Apple Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episode- Legionnaires’ Disease: In Harlem (NYC Health)
- 2 dead, dozens sickened by Legionnaires’ disease in Westchester County: Officials (NBC News)
- Invasive longhorned tick found for 1st time in New England (AP News)
- First person bitten by east Asian longhorned tick (AP News)
- Invasive, disease-carrying tick found in Maine, the farthest northeast it has been spotted (AP News)
- Suspected cases rise in DR Congo Ebola outbreak (CIDRAP)
- Ebola in the Democratic Republic of the Congo (CDC: Travelers’ Health)
- Patricia Mazzei (NY Times)
- Florida Moves to End Vaccine Mandates for Schoolchildren (NY Times)
- Wastewater for measles (WasterWater Scan)
- Measles cases and outbreaks (CDC Rubeola)
- Tracking Measles Cases in the U.S. (Johns Hopkins)
- Measles vaccine recommendations from NYP (jpg)
- Weekly measles and rubella monitoring (Government of Canada)
- Measles (WHO)
- Get the FACTS about measles (NY State Department of Health)
- Measles (CDC Measles (Rubeola))
- Measles vaccine (CDC Measles (Rubeola))
- Presumptive evidence of measles immunity (CDC)
- Contraindications and precautions to measles vaccination (CDC)
- Measles (CDC Measles (Rubeola))
- Adverse events associated with childhood vaccines: evidence bearing on causality (NLM)
- Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America)
- Deaths following vaccination: what does the evidence show (Vaccine)
- Influenza: Waste water scan for 11 pathogens (WastewaterSCan)
- Influenza-Associated Hospitalizations During a High Severity Season — Influenza Hospitalization Surveillance Network, United States, 2024–25 Influenza Season (CDC: MMWR)
- US respiratory virus activity (CDC Respiratory Illnesses)
- Respiratory virus activity levels (CDC Respiratory Illnesses)
- Weekly surveillance report: clift notes (CDC FluView)
- Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA)
- RSV: Waste water scan for 11 pathogens (WastewaterSCan)
- Risk factors for severe outcomes of respiratory syncytial virus infection in children (LANCET: Regional Health Europe)
- US respiratory virus activity (CDC Respiratory Illnesses)
- RSV-Network (CDC Respiratory Syncytial virus Infection)
- Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV))
- Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP)
- Evidence to Recommendations Framework (EtR): RSV Vaccination in Adults Aged 50–59 years (CDC: National Center for Immunization and Respiratory Diseases)
- Waste water scan for 11 pathogens (WastewaterSCan)
- COVID-19 deaths (CDC)
- Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses)
- COVID-19 national and regional trends (CDC)
- COVID-19 variant tracker (CDC)
- SARS-CoV-2 genomes galore (Nextstrain)
- Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV)
- Spillover of SARS-CoV-2 to domestic dogs in COVID-19–positive households: A one health surveillance study (Virus Research)
- Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula (Pfizer)
- Minnesota, New York issue executive orders promoting access to COVID vaccines (CIDRAP)
- No. 52: Declaring a Disaster in the State of New York Due to Federal Actions Related to Vaccine Access(NY State: Executive Order #52)
- Where to get pemgarda (Pemgarda)
- EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
- Infusion center (Prime Fusions)
- CDC Quarantine guidelines (CDC)
- NIH COVID-19 treatment guidelines (NIH)
- Drug interaction checker (University of Liverpool)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- What to do when sick with a respiratory virus (CDC)
- Managing healthcare staffing shortages (CDC)
- Patient-Reported Outcomes of Nirmatrelvir Treatment for High-Risk, Nonhospitalized Adults With Symptomatic COVID-19 (OFID)
- Real-world effectiveness of nirmatrelvir-ritonavir against severe outcomes of COVID-19 in Taiwan (OFID)
- PAXLOVID-nirmatrelvir and ritonavir : highlights of prescribing information (Pfizer)
- Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer)
- PAXCESSTM offers access and affordability options to patients prescribed PAXLOVIDTM (nirmatrelvir tablets; ritonavir tablets) (PAXCESS)
- Steroids,dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Daniel Griffin’s evidence based medical practices for long COVID (OFID)
- Long COVID hotline (Columbia : Columbia University Irving Medical Center)
- The answers: Long COVID
- Clinical trials explore how Low-Dose Naltrexone could help people with Long COVID (The Sick Times)
- Three clinical trials for Long COVID are testing JAK inhibitors to treat immune dysregulation (The Sick Times)
- Research updates, July 29: Stellate ganglion blocks, may help reduce the severity of some symptoms of Long COVID and ME (The Sick Times)
- New Long COVID and complex disease center at Mount Sinai set to be a leader in research, clinical care (The Sick Times)
- RECOVER-TLC announces new Long COVID clinical trials, receives mixed reactions from patient community (The Sick Times)
- Reaching out to US house representative
- Letters read on TWiV 1252
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene Ramsey. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Content in this podcast should not be construed as medical advice.
The AI-powered Podcast Player
